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Background: Reconsideringwhen to initiate renal replacement therapy (RRT) in patientswith chronic
kidneydisease (CKD)hasbeenemphasized recently.With evolvingmodern agedanddiabetes-prone
populations, conventional markers of uremia are not sufficient for determining the optimal timing
for dialysis initiation. This retrospective cohort study examined the association between hyper-
phosphatemia and uremic patients who need RRT registration.
Methods: All patients from the department of nephrology in one tertiary medical center in northern
Taiwanwhohad advancedCKDandestimated glomerular filtration rates<8mL/min/1.73m2 from July
2009 toMay 2013were enrolled.Wereviewed themedical records and collected data ondemographics,
comorbidities, underlying diseases, duration of nephrology care, use of phosphate binders, and labo-
ratory results. Univariable and multivariable logistic regression models were used to identify factors
associated with hemodialysis initiation decision making.
Results: During the study period, 209 of 292 patients with advanced CKD were enrolled in hemo-
dialysis program and 83 patients (controls) were not. Univariable analysis indicated that male sex,
current smoking, diabetes mellitus, hypertension, coronary artery disease, high serum creatinine
level, and high serum phosphate level were associated with initiation of hemodialysis. Multivari-
able analysis indicated that those with higher serum phosphate level (odds ratio [OR] ¼ 2.4, 95%
confidence interval [CI] ¼ 1.6e3.5, p ¼ 1.4  105) and being in nephrology care for <12 months
(OR ¼ 0.4, 95% CI ¼ 0.2e0.8, p ¼ 0.016) tended to be significant markers for hemodialysis initiation.
Conclusion: Hyperphosphatemia, in addition to conventional laboratory markers and uremic
symptoms, may be a useful marker to determine timing of hemodialysis initiation in patients
with advanced CKD.rology, Chang Gung Memorial Hospital at Linkou, 5 Fusing St., Geuishan, Taoyuan, Taiwan,
73.
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Scientific background on the subject
If left untreated, patients with advanced chronic kidney
disease (CKD) may die from progressively developed
uremic symptoms. The conventional markers for poor
kidney function may not always be useful to help
physician to decide when to initiate dialysis. Significant
hyperphosphatemia occurred in CKD patients who
chose to delay initiation of renal replacement therapy.
What this study adds to the field
In CKD patients with estimated glomerular filtration
rates <8 mL/min/1.73 m2, hyperphosphatemia was the
most significant factor associated with dialysis initiation
among other conventional uremic markers. Diabetic
nephropathy as a cause of end-stage renal disease was
also associated with dialysis initiation. Nephrology care
for more than 12 months was associated with reduced
risk of dialysis initiation.If leaving untreated, patients with advanced chronic kidney
disease (CKD) may die from progressively developed uremic
symptoms that are overwhelming and life-threatening (such
as pulmonary edema, extreme hyperkalemia, and ventricular
arrhythmia) or chronic and debilitating (e.g., general malaise,
frequent vomiting, poor appetite, and malnutrition) [1]. Renal
replacement therapy (RRT) is a trade-off medical decision and
indicated in these CKD patientswhen the benefits of treatment
(reducing the risk of death and improvement of patient well-
being) outweigh the risks of therapeutical complications, the
psychosocial inconvenience, and the financial burden of
health insurance [2]. As the life expectancy and poverty con-
tinues to improve worldwide, there is a high popularity of CKD
in the elderly [3]. This is attributable mainly to increasing
prevalence of aging- and lifestyle-related risk factors for CKD
such as diabetes, hypertension, and cardiovascular disease
[4,5]. These comorbidities also enable elder CKD patients
particularly susceptible to injury compared with younger CKD
patients with the same serum level of uremic toxins. Thus, the
conventional markers for poor kidney function e elevated
serum urea level, high serum creatinine (SCr) concentration,
and low estimated glomerular filtration rate (eGFR) emay not
be always useful to help physician to decide when to initiate
RRT in advanced CKD patients.
Since the publication of the kidney disease outcomes
quality initiative guidelines in 2002 indicating dialysis initia-
tion at glomerular filtration rate (GFR) below 15 mL/min/
1.73 m2 plus proper risk-benefit analysis [6], there had been a
trend toward earlier start of dialysis. Previous research sug-
gested that early initiation of dialysis was associated with
decreased mortality, hospitalization rate, and total costs [7].
However, several recent studies did not support this strategy.
In particular, these recent studies showed that early initiation
of dialysis in patients with eGFR of 10e15 mL/min/1.73 m2
provided no apparent clinical benefit and might increase therisk of death [8e11]. The 2012 Kidney Disease Improving
Global Outcomes guidelines for CKD suggest initiation of
dialysis when a patient experiences symptoms or signs
attributable to kidney failure, an inability to control volume
status or blood pressure, a progressive deterioration in nutri-
tional status refractory to dietary intervention, or cognitive
impairment [12]. This often, but not always, occurs in patients
with eGFRs from 5 to 10 mL/min/1.73 m2. However, these
uremic symptoms are partially based on patient perceptions
and physician judgments, so more objective laboratory pa-
rameters are needed to help deciding when to initiate dialysis
in advanced CKD patients, especially in countries or areas
where practicing nephrologists are scarce.
Phosphorus is a major intracellular anion and more than
90% of the body's phosphorus is in bone and soft tissue. Serum
phosphorus accounts for <1% of the body's total phosphorus
amount, but is a surrogate marker of total body phosphate
content. Phosphate homeostasis depends on dietary intake,
bone absorption, and renal excretion. Parathyroid hormone
(PTH), 1,25 (OH)2 Vitamin D3, and fibroblast growth factor 23-
klotho axis regulate the level of serum phosphate [13]. A
sharp decline in the GFR leads to reduce renal excretion of
phosphate and disruption of the hormonal regulatory process.
Therefore, patients with advanced CKD typically retain
phosphate and develop hyperphosphatemia. Previous
research indicated that significant hyperphosphatemia
occurred in CKD patients whowere under intensive treatment
and who chose to delay initiation of RRT [14]. However, it is
unknown if hyperphosphatemia can be used as an indicator
for initiation of RRT in such patients.
Thepurposeof this retrospectivestudy is toexamine the role
of serum phosphate level in advanced CKD and the potential
use of hyperphosphatemia to guide the initiation of RRT.Methods
Patient population
This study examined the records of all patients with Stages
3e5 CKD, who were under care in one Tertiary Medical Center
in Northern Taiwan from July 2009 to May 2013. The eGFR was
calculated by modification of diet in the renal disease equa-
tion [15], which considers age, gender, and SCr level.
Advanced CKD patients defined as with eGFRs <8 mL/min/
1.73 m2 were included. This study evaluated the role of serum
phosphate level on the need for long-term dialysis in patients
with CKD, so patients with the following characteristics were
excluded: younger than 18 years, significant episode of acute
kidney injury before dialysis (including sepsis, shock, dehy-
dration, acute heart or liver failure, contrast nephropathy, or
obstructive uropathy), initiation of dialysis because of bilat-
eral nephrectomy, choice of peritoneal dialysis rather than
hemodialysis. The Institutional Review Board of our institu-
tion approved the review and usage of patient medical data.
Dialysis initiation
Nephrologists and CKD nurses implemented an integrated
education program for patients with Stages 3e5 CKD that
Table 1 e Demographic and clinical characteristics of
patients with advanced chronic kidney disease who did
not start (control) or did start hemodialysis during the
study period (n ¼ 292).
Characteristic Control
(n ¼ 83)a
Dialysis-
initiated
(n ¼ 209)a
Pb
Age (years) 62.7 ± 11.7 63.1 ± 14.8 0.7947
Gender
Female 49 (59.0) 92 (44.0) 0.0270
Male 34 (41.0) 117 (56.0)
BMI (kg/m2) 24.3 ± 3.4 24.0 ± 4.4 0.1957
Current smoker 3 (3.6) 35 (16.7) 0.0018
Coexisting diseases
Diabetes 31 (37.4) 125 (59.8) 6.8  104
Hypertension 58 (69.9) 179 (85.7) 0.0027
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alysis was recommended after consideration of the patient's
detailed clinical history, physical examination, laboratory
data, and imaging results from the outpatient or emergency
departments. The training of our physicians followed the
updated guidelines and used the same consensus about the
indication of dialysis initiation. Most patients initiated he-
modialysis due to significant uremic symptoms, with fluid or
electrolyte imbalance, and met the current criteria for RRT
including: azotemia with persisting nausea and vomiting,
severe acidosis, fluid overload with significant shortness of
breath, marked hyperkalemia with or without cardiac
dysrhythmia, and uremic encephalopathy with altered level
of conscious.
Clinical data
We reviewed themedical records of patients to collect data on
demographics, comorbidities, underlying diseases, duration
of nephrology care, use of phosphate binders, and laboratory
results. All laboratory examinations were processed in the
department of laboratory medicine, which is certificated by
the College of American Pathologists. Patients were divided
into a dialysis-initiated group and a control (nondialysis)
group. Laboratory examinations prior to the initiation of he-
modialysis (dialysis-initiated group) and the last outpatient
laboratory examination (control group)were used for analysis.
The laboratory parameters were hemoglobin (Hb), hematocrit
(Hct), serum blood urea nitrogen (BUN), SCr, sodium (Na),
potassium (K), calcium (Ca), phosphate (P), albumin, and car-
bon dioxide (CO2). Predialysismeasurements of PTH and blood
gases were only available for a few patients, so these param-
eters were not analyzed. Coexisting diseases and underlying
causes of CKD, such as diabetes mellitus (DM), hypertension,
and glomerulonephritis (GN), were included in the analysis.
The duration of care in the nephrology clinic, prescription of
phosphate binders, and a daily dose of calcium (in meq) were
reviewed and analyzed.Coronary artery disease 3 (3.6) 36 (17.2) 0.0011
Malignancy 8 (9.6) 14 (6.7) 0.4610
Liver cirrhosis 1 (1.2) 7 (3.4) 0.4476
Primary cause of ESRD
Diabetes 26 (31.3) 119 (56.9) 3.0  104
Glomerulonephritis 41 (49.4) 68 (32.5)
Hypertension 8 (9.6) 6 (2.9)
Interstitial nephritis 2 (2.4) 1 (0.5)
Hereditary kidney disease 1 (1.2) 6 (2.9)
Others 5 (6.0) 9 (4.3)
Duration of nephrology care
12 months 20 (24.4) 112 (53.6) 7.0  106
>12 months 62 (75.6) 97 (46.4)
Use of phosphate binder
Yes 49 (59.1) 87 (41.6) 0.0910
No 34 (41.0) 122 (58.4)
Daily dose of calcium as
phosphate binder (meq)c
32.2 ± 16.8 40.7 ± 19.9 0.0121
Abbreviations: SD: standard deviation; BMI: body mass index;
ESRD: end-stage renal disease.
a Mean ± SD or n (%).
b p value is from Fisher's exact test for gender and the t-test for
continuous factors.
c For patients who took phosphate-binders.Statistical analysis
The demographics, clinical characteristics, and laboratory
results of patients who did and did not start hemodialysis
during the study period were summarized using descriptive
statistics, and compared using the t-test (continuous factors)
or Fisher's exact test (categorical factors). Potential risk factors
associated with the initiation of dialysis were evaluated using
logistic regression models with univariable and multivariable
analysis. For variable selection in themultivariablemodel, the
associations among the factors were evaluated to prevent
multicollinearity. For analysis of the associations between
two factors, Pearson's correlation testwas used for continuous
factors, and Fisher's exact test was used for categorical fac-
tors. The final multivariable model was based on backward
selection, with entry and removal criteria at a p ¼ 0.05 (with
entry and removal criteria at a p ¼ 0.05) among those with a
p < 0.05 in the univariate model. All analyses were performed
using SAS version 9.3 (SAS Institute, Cary, NC). All statistical
tests were two-sided and attained significance at a- ¼ 0.05.Results
Demographic and clinical characteristics
We retrospectively enrolled 292 patients with advanced CKD
who had eGFRs <8mL/min/1.73 m2 from July 2009 to May 2013
[Table 1]. A total of 209 patients started hemodialysis during
the study period, and the other 83 patients constituted the
control (nondialysis) group. The dialysis-initiated and control
groups were similar in age, body mass index (BMI), prevalence
of underlying malignancies, and liver cirrhosis. However, pa-
tients in the dialysis-initiated group were more likely to be
male (56% vs. 41%, p ¼ 0.027) and current smokers (16.7% vs.
3.6%, p ¼ 0.0018), and to have coexisting DM (59.8% vs. 34.7%,
p ¼ 6.8  104), hypertension (85.7% vs. 69.9%, p ¼ 0.0027), and
coronary artery disease (17.2% vs. 3.6%, p ¼ 0.0011). The pri-
mary causes of CKD in both groups were DM and GN. We
classified the primary cause of CKD as a binary variable (DM
vs. others) because GN and other nonDM categories had
similar impact on dialysis. Based on this classification, DM
Table 2 e Laboratory results of patients with advanced
CKD who did not start (control) or did start hemodialysis
during the study period (n ¼ 292).
Characteristic Control
(n ¼ 83)a
Dialysis-
initiated
(n ¼ 209)a
Pb
Albumin (g/dL) 4.0 ± 0.5 3.3 ± 0.5 8.6  109
BUN (mg/dL) 80.2 ± 20.2 123.0 ± 41.9 1.5  1025
Serum creatinine (mg/dL) 8.1 ± 1.9 11.3 ± 4.1 1.5  1017
eGFR (mL/min/1.73 m2) 6.0 ± 1.2 4.6 ± 1.5 4.4  1013
Calcium (meq/L) 8.4 ± 0.7 8.0 ± 1.0 0.0002
Phosphate (meq/L) 4.9 ± 0.8 7.0 ± 2.4 2.2  1025
Sodium (meq/L) 138.8 ± 3.7 135.7 ± 6.2 0.0006
Potassium (meq/L) 4.5 ± 0.7 4.6 ± 1.0 0.4955
Hemoglobin (g/dL) 9.2 ± 1.4 8.5 ± 1.4 0.0005
Hematocrit (%) 28.1 ± 4.1 25.6 ± 4.3 7.9  106
CO2 (meq/L) 19.5 ± 5.7 17.1 ± 5.9 0.0789
Abbreviations: SD: standard deviation; BUN: blood urea nitrogen;
eGFR: estimated glomerular filtration rate; CO2: carbon dioxide;
CKD: chronic kidney disease.
a Mean ± SD.
b P value is from Fisher's exact test.
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group (56.9% vs. 31.3%, p ¼ 3  104).Laboratory results
Analysis of laboratory data [Table 2] indicated that the
dialysis-initiated group had significantly lower serumTable 3eUnivariable andmultivariable analysis of factors asso
(n ¼ 292).
Characteristic Univa
OR (95% CI)
Age, in 10 years 1.0 (0.9e1.2)
Male 1.8 (1.1e3.1)
BMI (kg/m2) 1.0 (0.9e1.1)
Current smoker 5.4 (1.6e18.0
Albumin (g/dL) 0.1 (0e0.2)
BUN, in 10 units (mg/dL) 1.6 (1.4e1.9)
Serum creatinine (mg/dL) 1.7 (1.4e1.9)
eGFR (mL/min/1.73 m2) 0.5 (0.4e0.6)
Calcium (meq/L) 0.6 (0.5e0.8)
Phosphate (meq/L) 2.9 (2.1e3.9)
Sodium (meq/L) 0.9 (0.8e1.0)
Potassium (meq/L) 1.1 (0.8e1.4)
Hemoglobin (g/dL) 0.7 (0.6e0.9)
Hematocrit (%) 0.9 (0.8e0.9)
CO2 (meq/L) 0.9 (0.9e1.0)
Coronary artery disease (yes vs. no) 5.5 (1.7e18.6
Coexisting diabetes (yes vs. no) 2.5 (1.5e4.2)
Coexisting hypertension (yes vs. no) 2.6 (1.4e4.7)
Coexisting malignancy (yes vs. no) 0.7 (0.3e1.7)
Primary cause of ESRD (diabetes vs. others) 2.9 (1.7e5.0)
Duration of nephrology care (>12 vs.12 months) 0.3 (0.2e0.5)
Use of phosphate binder (yes vs. no) 0.5 (0.3e0.8)
Abbreviations: CI: confidence interval; OR: odds ratio; BUN: blood urea n
renal disease; CO2: carbon dioxide; BMI: body mass index.
a OR and 95% CI based on logistic regression.
b A factor considered in variable selection for a multivariable model thaalbumin (3.3 vs. 4.0 g/dL, p ¼ 8.6  109), eGFR (4.6 vs. 6.0 mL/
min/1.73 m2, p ¼ 4.4  1013), Ca (8.0 vs. 8.4 meq/L, p ¼ 0.0002),
Na (135.7 vs. 138.8 meq/L, p ¼ 0.0006), Hb (8.5 vs. 9.2 g/dL,
p ¼ 0.0005), and Hct (25.6% vs. 28.1%, p ¼ 7.9  106). As ex-
pected, the dialysis-initiated group also had significantly
higher serum BUN (123.0 vs. 80.2 mg/dL, p ¼ 1.5  1025) and
SCr (11.3 vs. 8.1 mg/dL, p ¼ 1.5  1017). In addition, the
dialysis-initiated group had significantly higher of serum P
(7.0 vs. 4.9 meq/L, p ¼ 2.2  1025). However, the two groups
had similar levels of serum K, presumably because a serum K
level above 6.5 meq/L can induce deadly cardiac arrhythmia,
and patients with this level of serum K are commonly placed
on dialysis programs.Univariable and multivariable analysis
Next, we examined the factors associated with initiation of
dialysis by univariable and multivariable logistic regression
models [Table 3]. Initially, we considered the associations
among factors to avoid multicollinearity. Thus, we excluded
SCr and Hct because these two factors were highly correlated
(Pearson's r ¼ 0.81), as were Hb and Hct (Pearson's r ¼ 0.97).
DM as the primary cause of renal disease and coexisting DM
were also highly associated (Fisher's exact p < 0.0001), so only
the former value was included in the multivariable model.
BMI, albumin, Na, and CO2 were omitted because there were
missing values (missing sample sizes of 169, 187, 78, and 193,
respectively). Liver cirrhosis, coronary artery disease,ciatedwith the initiation of dialysis during the study period
riable analysis Multivariable analysisb
a p OR (95% CI)a p
0.8126
0.0213 e
0.8044
) 0.0064
3.8  106
3.0  1012 1.4 (1.2e1.7) 1.9  105
5.4  1010
1.1  1010 0.6 (0.5e0.8) 0.0020
0.0012 e
4.2  1012 2.1 (1.4e2.9) 9.8  105
0.0135
0.5597
0.0007 e
2.1  105
0.0865
) 0.0054
0.0006
0.0023 e
0.3930
0.0001 5.3 (2.4e11.8) 3.1  105
1.3  105 0.4 (0.2e0.8) 0.0171
0.0076 e
itrogen; eGFR: estimated glomerular filtration rate; ESRD: end-stage
t was not significant (P > 0.05).
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the small number of positives in the control group.
Thus, we entered 10 variables into the multivariable anal-
ysis: sex, five laboratory markers (BUN, eGFR, Ca, P, and Hb),
coexisting hypertension, primary cause of CKD (DM vs.
others), duration of nephrology care, and use of a phosphate
binder. Five of these factors were significantly and indepen-
dently associated with the initiation of dialysis. In particular,
the two conventional laboratory parameters for initiation of
dialysis, BUN (odds ratio [OR] ¼ 1.4, 95% confidence interval
[CI] ¼ 1.2e1.7) and eGFR (OR ¼ 0.6, 95% CI ¼ 0.5e0.8) were
significantly associated with initiation of dialysis. After
adjusting for other factors, serum P was one of the most sig-
nificant factor associated with initiation of dialysis (OR ¼ 2.1,
95% CI¼ 1.4e2.9, p¼ 9.8 105), with a 110% increased risk for
initiation of dialysis for each 1 mg/dL increase of serum P.
Diabetic nephropathy as a cause of end-stage renal disease
(ESRD) was also highly associated with initiation of dialysis
(OR ¼ 5.3, 95% CI ¼ 2.4e11.8). Longer duration of nephrology
care (>12 months) was significantly associated with reduced
risk of initiation of dialysis (OR ¼ 0.4, 95% CI ¼ 0.2e0.8).Discussion
Taiwan has among the highest prevalence and incidence rates
of advanced CKD patients who receive hemodialysis world-
wide [16]. A previous report on the epidemiology of CKD in
Taiwan indicated very low awareness of this disease; aware-
ness was only 3.5% for patients with Stages 1e5 CKD and was
51.4% for predialysis patients with Stage 5 CKD [17]. Analysis
of the Taiwan national database showed that advanced CKD
patients tended to start dialysis when they had very low re-
sidual renal function (median eGFR of 4.7 mL/min/1.73 m2),
and division of patients into quintiles indicated that even
those in the highest quintile had amedian eGFR¼ 7.7mL/min/
1.73 m2 [18]. This delay in the initiation of dialysis may be due
to a lack of awareness or fear and reluctance to initiate dial-
ysis. CKD patients in our institute also tend to start dialysis
therapy late, after the development of serious or life-
threatening uremic symptoms. Therefore, our study cohort
consisted of patients with advanced CKD (eGFR <8 mL/min/
1.73 m2), so that we could clarify the usefulness of serum
phosphate level, conventional uremic markers, and symp-
toms to determine the optimal time for hemodialysis
initiation.
Nephrologists and CKD nurses in our institute imple-
mented an integrated multidisciplinary predialysis education
(MPE) program to care patients since they were defined with a
Stage 3 CKD [19]. This program emphasizes intake fluid and
blood pressure control, dietary education about protein,
phosphate, and potassium restriction, and the use of phos-
phate binders, multi-Vitamin B, folic acid supplements, and
erythropoietin injections for anemia. Associated goals are the
introduction of different dialysis modalities, preparation for
dialysis access, and timely initiation of RRT for patients with
late-stage CKD (Stages 4 and 5). This MPE program is proved to
delay effectively the need for dialysis and to reduce the co-
morbidities and unexpected mortality in patients with late-
stage CKD [19]. In agreement with medical literatures, ourresults of the present study also indicated that a longer
duration of predialysis nephrology care and CKD education
(>12months) reduced the risk for initiation of hemodialysis by
about 60%.
Comparison of our control and dialysis-initiated groups
indicated that slightly fewer patients in the dialysis-initiated
group took phosphate-binders, although their average daily
dose was significantly greater, and their phosphate control
was significantly worse. Thismay be explained as a composite
result of their worsening glomerular filtration, compliance to
dietary restrictions, and use of phosphate binders.
Our analysis of laboratory parameters indicated that BUN,
SCr, eGFR, and serum P were most significantly different be-
tween the dialysis-initiated and control groups. BUN, SCr, and
eGFR are conventionally used to indicate poor renal function
and the need for dialysis. It is particularly noteworthy that our
two groups had very different serum P levels, and serum Pwas
the only tested parameter that waswithin the normal range in
the control group (4.9 ± 0.8mg/dL), but severely elevated in the
dialysis-initiated group (7.0 ± 2.4 mg/dL). In addition, our
multivariable analysis indicated that serum P was one of the
most significant laboratory factor associated with initiation of
dialysis (OR ¼ 2.1). In other words, there was a 110% increased
risk for starting dialysis for every 1 mg/dL increase of serum P.
This may be reasonably explained that significant hyper-
phosphatemia in the dialysis-initiated group was parallel to
the deterioration of residual renal function and the level of
phosphate retention. However, this is also similar to high
serum BUN and creatinine level, which are accepted as the
traditional markers for renal failure and indicating the ne-
cessity of RRT initiation. In those patients with complex ure-
mic syndrome, especially in aged and diabetes-prone
populations, more laboratory data to judge the indication of
dialysis initiation is justified, and hyperphosphatemia fulfills
this purpose well. The cut-off value of high serum phosphate
level as an indicator for dialysis initiation is not clearly defined.
Hyperphosphatemia plays an important role in mineral
bone diseases and vascular calcifications, and is associated
with increased risk of progression to ESRD, cardiovascular
events, and all-cause mortality in CKD patients [20e23].
Hyperphosphatemia is not in itself immediately harmful and
may have numerous underlying causes, and serumphosphate
level is not regularly used as an indicator for starting dialysis in
clinical practice, effective, and aggressive management of
chronic hyperphosphatemia is warranted. Phosphate reten-
tion is common in patients with advanced CKD, and hemodi-
alysis can effectively lower serum phosphate when
conservative treatments fail. As demonstrated in this study,
high serum phosphate level is a strong predictor for advanced
CKD patients who were decided by experienced physicians to
be enrolled in hemodialysis program because of severe fluid
retention, hyperkalemia, acidosis and other uremic symp-
toms. Based on these findings, we suggest that clinicians
consider the use of serum P as a laboratory marker in the
decision-making process to initiate dialysis in advanced CKD
patients.
There were several limitations in this study. First, it was a
retrospective, single-hospital study, and the study cohort was
relatively small. Second, patient compliance to our MPE pro-
gram varied widely, and we were not able to access the daily
b i om e d i c a l j o u r n a l 3 8 ( 2 0 1 5 ) 5 3 1e5 3 7536phosphate intake in all patients. Furthermore, the use of
phosphate binders is not reimbursed by the Taiwan National
Health Insurance, so socioeconomic status, in addition to the
clinical factors thatwe identified,may have affected the use of
phosphate binders. Finally, a large randomized outcome trial
that examines mortality and cardiovascular complications
and uses hyperphosphatemia as the criterion to enter dialysis
is needed to better define the role of serum phosphate in
predicting the need for dialysis in patients with advanced
CKD.Conclusion
Hyperphosphatemia is not only a common electrolyte prob-
lem in patients with advanced CKD, but is also well known as
a significant risk factor for mineral bone diseases, vascular
calcification, and cardiovascular and all-cause mortality in
these patients. Based on this study, we further recommend
that in addition to conventional laboratory parameters and
uremic symptoms, clinicians could consider significant
hyperphosphatemia as a reliable marker to determine initia-
tion of dialysis in patients with advanced CKD.Source of support
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